This program will explore key findings from a large global survey of health care providers and patients, uncovering unmet needs in patient care and key barriers to adoption of immunotherapies for relapsed/refractory multiple myeloma. Current treatment options, including practical considerations for the use of elranatamab, a BCMA-directed bispecific immunotherapy for certain adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, will also be discussed.